Known as tiplaxtinin (PAI-039), this oral antagonist of endogenous PAI-1 has been shown to demonstrate a myriad of beneficial effects ranging from antithrombotic properties to attenuating the degree of insulin resistance, adiposity, and body weight [41]. Here, SERPINE1 is linked to Insulin resistance.